Newleos Therapeutics
Hector Guzman currently serves as Vice President of CMC and Technical Operations at Newleos Therapeutics since May 2025. Prior to this role, Guzman held the position of Vice President of Technical Operations at Lyndra Therapeutics from March 2022 to April 2025. At Alkermes, Guzman advanced through several roles including Executive Director, Sr. Director, Director, Associate Director, and Principal Engineer in Process Development from March 2009 to March 2022. Guzman's early career included a tenure as Principal Scientist in Formulation Development at TransForm Pharmaceuticals, a Johnson & Johnson company, from November 2001 to February 2009. Academic credentials include a Doctor of Philosophy in Chemical Engineering from the Georgia Institute of Technology and a Bachelor of Science in Chemical Engineering from The Johns Hopkins University.
This person is not in any teams
This person is not in any offices
Newleos Therapeutics
We are dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. Our clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development.